1 / 12

Diagnosis & Management of Diabetic Eye Disease Part 7

Diagnosis & Management of Diabetic Eye Disease Part 7. A. Paul Chous, M.A., O.D., F.A.A.O. Tacoma, WA Specializing in Diabetes Eye Care & Education. Newest Therapies for DR. VEGF Inhibitors: Macugen TM , Lucentis TM , Avastin TM in trials

kwines
Download Presentation

Diagnosis & Management of Diabetic Eye Disease Part 7

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Diagnosis & Management of Diabetic Eye DiseasePart 7 A. Paul Chous, M.A., O.D., F.A.A.O. Tacoma, WA Specializing in Diabetes Eye Care & Education

  2. Newest Therapies for DR • VEGF Inhibitors: MacugenTM, LucentisTM, AvastinTM in trials • Macugen & Lucentis both improved VA and reduced OCT thickness in DME • Macugen & Avastin caused regression of PDR; Avastin reduced iris neovascularization • Avastin caused rapid resolution of VH (n=2) • DRCR.net now links multiple researchers & centers

  3. VEGF in Diabetic Retinopathy • Retinal VEGF levels elevated in experimental diabetes • VEGF165 injected in primates induces vascular leakage within 30 minutes • Increased VEGF levels found in vitreous of eyes with proliferative DR & DME • DR patients have higher VEGF levels in the aqueous Quam et al. IOVS. 2001; Tolentino et al. Ophthalmology. 1996; Funatsu et al. AJO. 2002; Adamis et al. AJO. 1994; Aiello et al. NEJM. 1994. Courtesy of Jeffry Gerson, O.D., F.A.A.O.

  4. Newest Therapies for DR • PKC Inhibitors: • Ruboxistaurin (ArxxantTM, Lilly/Alcon) showed modest benefit for DME • FDA approval in question • Inflammatory Modulators: • Steroids reduce VEGF production (IV/sub-tenon’s) • Sustained release steroids: RetisertTM, AlimeraTM, PosurdexTM • Infliximab: a monoclonal antibody against TNF-a that inhibits breakdown of the blood-retinal barrier (in trials)

  5. Newest Therapies for DR • Micro-pulsed laser: lower duration & energy causes less retinal damage, possibly less severe scotomata and improved scotopic visual function • Nutraceuticals • Benfotiamine: fat-soluble form of thiamine that blocks all 4 biochemical pathways of hyperglycemic insult in vivo & totally prevented DR in rats • Pycnogenol: patented pine bark extract reduces capillary leakage and reduced retinal thickening in one RCCT of DME

  6. Newest Therapies for DR Low energy laser: Reduces visual field Defects, improves Night vision, lower Risk of pain during procedure SDM Laser Sub-threshold Diode Micropulse Laser

  7. By dramatically increasing levels of intracellular thiamine, benfotiamine reduces F-6-P and G-3-P via the pentose phosphate shunt Glucose Metabolism Glucose Polyol Pathway Glucose-6-phosphate Fructose-6-phosphate Hexosamine Flux Glyceraldehyde-3-phosphate G-3-P Protein Kinase C Advanced Glycation Endproducts GAPDH 1,3 Diphosphoglycerate (harmless metabolite)

  8. Benfotiamine Update • A recent trial of 600 mg benfotiamine daily for 3 weeks in patients with longstanding T1DM • Normalized elevated activity in: • Polyol Pathway • Hexosamine Pathway • AGE Pathway • PKC not assessed (too much blood required) Brownlee M. Diabetologia Sept 2008

  9. Effective Communication Use positive language Avoid scare tactics Build a Relationship through Knowledge & Compassion • Clear explanation of the patient’s ocular conditions & treatment options • Information about the link between diabetes & eye disease (& vice versa) • Realistic appraisal of the individual risk of vision loss • risk of blindness < risk of CV disease • risk of blindness ranges from 0.5%-19%

  10. Key Points • Diabetes and diabetic eye disease are epidemic • Ocular complications are myriad and associated with large blood vessel disease • State-of-the-art care is evolving rapidly

  11. “The only thing to do with good advice is to pass it on to others… It is of absolutely no use to oneself.” - Oscar Wilde

  12. Thank You!! • Paul Chous, O.D. • dr.chous@diabeticeyes.com

More Related